Share Email Print

Proceedings Paper

Transcranial laser therapy alters amyloid precursor protein processing and improves mitochondrial function in a mouse model of Alzheimer's disease
Author(s): Thomas McCarthy; Jin Yu; Salim El-Amouri; Sebastiano Gattoni-Celli; Steve Richieri; Luis De Taboada; Jackson Streeter; Mark S. Kindy
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Transcranial laser therapy (TLT) using a near-infrared energy laser system was tested in the 2x Tg amyloid precursor protein (APP) mouse model of Alzheimer's Disease (AD). TLT was administered 3 times/week at escalating doses, starting at 3 months of age, and was compared to a control group which received no laser treatment. Treatment sessions were continued for a total of six months. The brains were examined for amyloid plaque burden, Aβ peptides (Aβ1-40 and Aβ1-42 ), APP cleavage products (sAPPα, CTFβ) and mitochondrial activity. Administration of TLT was associated with a significant, dose-dependent reduction in amyloid load as indicated by the numbers of Aβ plaques. Levels of Aβ1-40 and Aβ1-42 levels were likewise reduced in a dose-dependent fashion. All TLT doses produced an increase in brain sAPPα and a decrease in CTFβ levels consistent with an increase in α-secretase activity and a decrease in β-secretase activity. In addition, TLT increased ATP levels and oxygen utilization in treated animals suggesting improved mitochondrial function. These studies suggest that TLT is a potential candidate for treatment of AD.

Paper Details

Date Published: 17 February 2011
PDF: 13 pages
Proc. SPIE 7887, Mechanisms for Low-Light Therapy VI, 78870K (17 February 2011); doi: 10.1117/12.877028
Show Author Affiliations
Thomas McCarthy, PhotoThera, Inc. (United States)
Jin Yu, Medical Univ. of South Carolina (United States)
Salim El-Amouri, Medical Univ. of South Carolina (United States)
Sebastiano Gattoni-Celli, Medical Univ. of South Carolina (United States)
Ralph H. Johnson VA Medical Ctr. (United States)
Steve Richieri, PhotoThera, Inc. (United States)
Luis De Taboada, PhotoThera, Inc. (United States)
Jackson Streeter, Banyan Biomarkers, Inc. (United States)
Mark S. Kindy, Medical Univ. of South Carolina (United States)
Neurological Testing Service, Inc. (United States)

Published in SPIE Proceedings Vol. 7887:
Mechanisms for Low-Light Therapy VI
Michael R. Hamblin; Ronald W. Waynant; Juanita Anders, Editor(s)

© SPIE. Terms of Use
Back to Top